Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ARAF | P10398 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | MYOC | Q99972 | 1/20 | 0.40 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370105 | 0.83 | MAPT (0.34) | MAPTTGM2HTTTDP1LRRK2 | |
| SCHEMBL5364320 | 0.75 | — | — | |
| SCHEMBL7135658 | 0.69 | — | — | |
| SCHEMBL23817603 | 0.68 | TGM2 (0.61) | MAPTAPPRAF1MAP1LC3BTGM2 | |
| SCHEMBL7133818 | 0.66 | MAPT (0.46) | MAPTAPPRAF1MAP1LC3BTGM2 | |
| SCHEMBL5358413 | 0.65 | RET (0.73) | MAPTAPPRAF1MAP1LC3BEGFR | |
| SCHEMBL5368858 | 0.65 | MAPT (0.62) | MAPTAPPRAF1MAP1LC3BEGFR | |
| SCHEMBL5363455 | 0.64 | MAPT (0.58) | MAPTAPPRAF1MAP1LC3BEGFR | |
| SCHEMBL5369976 | 0.63 | MAPT (0.62) | MAPTAPPRAF1MAP1LC3BEGFR | |
| SCHEMBL6687938 | 0.63 | CSNK1D (0.71) | MAPTAPPRAF1MAP1LC3BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MAPT 3048/4885APP 3124/4885RAF1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.